Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy.

Technology in cancer research & treatment - 1 Jan 2026

Zhong Deyuan, Liang Yuxin, Su Yuhao, Yang Qinyan, Yan Hongtao, Huang Xiaolun, Shang Jin

Abstract excerpt

IntroductionDespite the advent of anti-PD-1 immunotherapy as a promising treatment for HCC, there remains a significant gap in the comprehensive analysis of peripheral blood immunological markers that could predict treatment response. This study aims to identify peripheral blood immunological markers predictive of anti-PD-1 therapy response in HCC patients to improve clinical outcomes.MethodsWe retrospectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Interleukin-10

Share to Interleukin-2

Share to Liver Neoplasms

Share to Programmed Cell Death 1 Receptor

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41642855
DOI: 10.1177/15330338261421357
PMCID: PMC12876621

Genes

FLT3
IDH2
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy.PMID 41642855Read ↗

Prognostic value of the ratio of Interleukin-2 and Interleukin-10 in patients with hepatocellular carcinoma treated with anti-PD-1 therapySemantic proximity Read ↗

Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular CarcinomaSemantic proximity Read ↗

Immune Microenvironment and Clinical Significance of PD1 Expression in Hepatocellular Carcinoma PatientsSemantic proximity Read ↗

Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular CarcinomaSemantic proximity Read ↗

Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictionsSemantic proximity Read ↗

Identification of Novel Immune-infiltration Related miRNAs that can Predict the Prognosis of Patients with Hepatocellular CarcinomaSemantic proximity Read ↗

Characterization and Clinical Verification of Immune-related Genes in Hepatocellular Carcinoma to Aid Prognosis Evaluation and ImmunotherapySemantic proximity Read ↗

A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.Semantic proximity Read ↗

Immune Cell Composition of Liver Hepatocellular Carcinoma and its clinical relevance: A research based on TCGA databaseSemantic proximity Read ↗

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinomaSemantic proximity Read ↗

Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.Semantic proximity Read ↗

Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.